Artigo de periodico

Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy (2019)

• Authors:
  • Saboia, Jaquellyne Gurgel Penaforte
  • Couri, Carlos Eduardo Barra
  • Fernandes, Virginia Oliveira
  • Montenegro, Ana Paula Dias Rangel
  • Batista, Lívia Aline de Araújo
  • Zajdenverg, Lenita
  • Negrato, Carlos Antonio
  • Farias, Kelen Cristina Ribeiro Malmegrim de
  • Moraes, Daniela Aparecida de
  • Dias, Juliana Bernardes Elias
  • Oliveira, Maria Carolina
  • Hussain, Akhtar
  • Gomes, Marilia Brito
  • Montenegro Junior, Renan Magalhães
• USP affiliated authors: FARIAS, KELEN CRISTINA RIBEIRO MALMEGRIM DE - FCFRP ; RODRIGUES, MARIA CAROLINA DE OLIVEIRA - FMRP
• Unidades: FCFRP; FMRP
• DOI: 10.3389/fendo.2019.00747
• Subjects: INSULINA; DIABETES MELLITUS; TRANSPLANTES; CÉLULAS-TRONCO
• Keywords: Type 1 diabetes (T1D); Residual B-cell function; Glycemic control; Microvascular complications
• Language: Inglês
• Imprenta:
  • Publisher place: Lausanne
  • Date published: 2019
• Source:
  • Título: Frontiers in Endocrinology
  • ISSN: 1664-2392
  • Volume/Número/Paginação/Ano: v. 10, art. 747, [7] p., 2019

Informações sobre o DOI: 10.3389/fendo.2019.00747 (Fonte: oaDOI API)
• Este periódico é de acesso aberto
• Este artigo NÃO é de acesso aberto
  

---

Download do texto completo

Tipo	Nome	Link
	003006177.pdf	Direct link

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  SABOIA, Jaquellyne Gurgel Penaforte et al. Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy. Frontiers in Endocrinology, v. 10, p. [7] , 2019Tradução . . Disponível em: https://doi.org/10.3389/fendo.2019.00747. Acesso em: 12 fev. 2026.

• APA

  Saboia, J. G. P., Couri, C. E. B., Fernandes, V. O., Montenegro, A. P. D. R., Batista, L. A. de A., Zajdenverg, L., et al. (2019). Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy. Frontiers in Endocrinology, 10, [7] . doi:10.3389/fendo.2019.00747

• NLM

  Saboia JGP, Couri CEB, Fernandes VO, Montenegro APDR, Batista LA de A, Zajdenverg L, Negrato CA, Farias KCRM de, Moraes DA de, Dias JBE, Oliveira MC, Hussain A, Gomes MB, Montenegro Junior RM. Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy [Internet]. Frontiers in Endocrinology. 2019 ; 10 [7] .[citado 2026 fev. 12 ] Available from: https://doi.org/10.3389/fendo.2019.00747

• Vancouver

  Saboia JGP, Couri CEB, Fernandes VO, Montenegro APDR, Batista LA de A, Zajdenverg L, Negrato CA, Farias KCRM de, Moraes DA de, Dias JBE, Oliveira MC, Hussain A, Gomes MB, Montenegro Junior RM. Lower Insulin-Dose Adjusted A1c (IDAA1c) is associated with less complications in individuals with type 1 diabetes treated with hematopoetic stem-cell transplantation and conventional therapy [Internet]. Frontiers in Endocrinology. 2019 ; 10 [7] .[citado 2026 fev. 12 ] Available from: https://doi.org/10.3389/fendo.2019.00747

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Editorial: immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
• New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
• Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases: where do we stand?
• Editorial: Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: Where do we stand? Volume II
• Immune profile after autologous hematopoietic stem cell transplantation for autoimmune diseases [Editorial]: where do we stand?
• Teplizumab in relatives at risk for type 1 diabetes. [Carta]
• New horizons in the treatment of type 1 diabetes: more intense immunosuppression and beta cell replacement
• Autologous hematopoietic stem cell transplantation for autoimmune diseases: from mechanistic insights to biomarkers
• CMV-specific clones may lead to reduced TCR diversity and relapse in systemic sclerosis patients treated with AHSCT [Carta]
• Avaliação da reconstituição imunológica em pacientes com diabete melito do tipo 1 e esclerose múltipla após transplante autólogo de células tronco hematopoéticas